Keyword: Fujifilm Diosynth Biotechnologies
Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.
A judge orders Allergan to turn over Botox production details; A U.S. senator urges the FDA to run surprise inspections; the FDA approves Daiichi's cancer drug.
CDMO Fujifilm Diosynth has acquired from Biogen a biologics production facility in Denmark with about 800 employees.
Fujifilm will buy biologics operations in Denmark from Biogen as the Japanese company continues to beef up its CDMO business.
Fujifilm to expand its production facility in North Carolina to support increased customer needs.
Drug materials are targets of U.S.-China trade war, analysts see more hope in the Takeda-Shire deal, China puts forward policies that favors generics over brands.
Fujifilm continues to expand its healthcare footprint with the recent acquisition of a pair of cell culture media units for about $800 million.
Japan’s Fujifilm will build a plant to produce liposomes that can be the delivery vehicles for some new drug candidates.
WuXi NextCODE has raised $240 million in series B, FDA slapped Celltrion with a long Form 483, Biocon's $275 million insulin plant opened shop.
Japan's Fujifilm Diosynth Biotechnologies has completed a $9 million expansion project of its cell manufacturing facilities in the U.K.
